Summary
Abbott Laboratories' Q3 2016 10-Q filing reveals a mixed financial performance, with total net sales increasing by 2.9% to $5.3 billion compared to the prior year's third quarter. This growth was primarily driven by the Established Pharmaceutical Products, Diagnostic Products, and Vascular Products segments, especially in international markets when excluding the impact of foreign exchange. However, the company reported a net loss of $329 million for the quarter, a significant decline from the $580 million net earnings in the same period last year. This was largely influenced by a substantial $947 million expense recorded to adjust the holding of Mylan N.V. ordinary shares due to a decline in their fair value, alongside other non-operating factors. The filing also highlights significant strategic developments, including the pending acquisitions of Alere Inc. and St. Jude Medical, Inc. These are transformative deals expected to reshape Abbott's business. The company is actively managing its portfolio, evidenced by the announced sale of Abbott Medical Optics (AMO) to Johnson & Johnson. Despite the quarterly net loss, the underlying operational performance, particularly in key growth areas and international markets, shows resilience.
Financial Highlights
54 data points| Revenue | $5.30B |
| Cost of Revenue | $2.29B |
| Gross Profit | $2.88B |
| SG&A Expenses | $1.63B |
| Operating Expenses | $4.41B |
| Operating Income | $897.00M |
| Interest Expense | $117.00M |
| Net Income | -$329.00M |
| EPS (Basic) | $-0.22 |
| EPS (Diluted) | $-0.22 |
| Shares Outstanding (Basic) | 1.48B |
| Shares Outstanding (Diluted) | 1.48B |
Key Highlights
- 1Total net sales for Q3 2016 increased by 2.9% to $5.3 billion, driven by growth in Pharmaceuticals, Diagnostics, and Vascular products, particularly in international markets excluding foreign exchange impacts.
- 2The company reported a net loss of $329 million for the quarter, a significant decrease from a net earning of $580 million in Q3 2015, largely due to a $947 million Mylan N.V. share value adjustment.
- 3Abbott is pursuing two major strategic acquisitions: Alere Inc. (diagnostics) and St. Jude Medical, Inc. (cardiovascular devices), which are expected to significantly expand its market presence.
- 4The company announced the sale of its vision care business (AMO) to Johnson & Johnson for $4.325 billion, signaling portfolio optimization.
- 5Foreign exchange headwinds negatively impacted international sales, decreasing total sales by 1.1% in Q3 2016.
- 6Research and development expenses saw a decrease of 6.7% in Q3 2016 compared to the prior year, primarily due to lower restructuring costs.
- 7The company continues to return capital to shareholders, with declared cash dividends per common share increasing by 8% year-over-year for the first nine months of 2016.